| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11673-014-9595-3 |
| P8608 | Fatcat ID | release_ihjigcnhcvfkbjmg3w3dchq4f4 |
| P698 | PubMed publication ID | 25630591 |
| P5875 | ResearchGate publication ID | 271597377 |
| P50 | author | Chris Degeling | Q47184137 |
| Christopher Mayes | Q58073358 | ||
| Wendy Lipworth | Q60731491 | ||
| Ian Kerridge | Q61313351 | ||
| P2093 | author name string | Ross Upshur | |
| P2860 | cites work | Drug development for neglected diseases: a deficient market and a public-health policy failure | Q28207953 |
| What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? | Q28485194 | ||
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| Accelerating resistance, inadequate antibacterial drug pipelines and international responses | Q30413178 | ||
| Drug-resistant tuberculosis: time for visionary political leadership | Q30428762 | ||
| Curing TB with open science | Q30486592 | ||
| Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis | Q33926262 | ||
| Discovery research: the scientific challenge of finding new antibiotics | Q33941796 | ||
| Tuberculosis, drug resistance, and the history of modern medicine | Q34296582 | ||
| The FDA reboot of antibiotic development | Q37263756 | ||
| Global tuberculosis drug development pipeline: the need and the reality. | Q37757660 | ||
| Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals | Q37785721 | ||
| New drugs for the treatment of tuberculosis: hope and reality | Q38023907 | ||
| New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects | Q38199573 | ||
| Access to medicines, market failure and market intervention: a tale of two regimes | Q39541569 | ||
| The future of bioethics: three dogmas and a cup of hemlock | Q39869790 | ||
| Apocalypse or redemption: responding to extensively drug-resistant tuberculosis. | Q41835600 | ||
| Attitudes towards involuntary incarceration for tuberculosis: a survey of Union members. | Q42232795 | ||
| The role of product development partnerships in advancing the development of drugs for unmet needs | Q43920251 | ||
| Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials | Q49368121 | ||
| Will longer antimicrobial patents improve global public health? | Q51103968 | ||
| Extreme condition, extreme measures? Compliance, drug resistance, and the control of tuberculosis. | Q53169625 | ||
| Bioethics as biopolitics. | Q53241397 | ||
| New malaise: bioethics and human rights in the global era. | Q53332093 | ||
| Sanatoria for drug-resistant tuberculosis: an outdated response | Q58485190 | ||
| The crisis of no new antibiotics—what is the way forward? | Q59485638 | ||
| Montréal Statement on the Human Right to Essential Medicines. | Q64985027 | ||
| XDR-TB: entering the post-antibiotic era? | Q79388538 | ||
| Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand | Q81569361 | ||
| Patients and the public deserve big changes in evaluation of drugs | Q83591451 | ||
| 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards | Q83851751 | ||
| The antibiotics market | Q84974080 | ||
| First novel anti-tuberculosis drug in 40 years | Q86081363 | ||
| Improving the health of the tuberculosis drug pipeline | Q87413108 | ||
| Sustainable tuberculosis drug development | Q87416065 | ||
| P433 | issue | 1 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| research ethics | Q1132684 | ||
| P304 | page(s) | 107-113 | |
| P577 | publication date | 2015-01-29 | |
| P1433 | published in | Journal of Bioethical Inquiry | Q15760847 |
| P1476 | title | The political and ethical challenge of multi-drug resistant tuberculosis | |
| P478 | volume | 12 |
| Q40932346 | Beyond Biomedicine: Relationships and Care in Tuberculosis Prevention | cites work | P2860 |
Search more.